Etoricoxib-Induced Erythema-Multiforme-Like Eruption

  title={Etoricoxib-Induced Erythema-Multiforme-Like Eruption},
  author={Laurence Thirion and Arjen F. Nikkels and G{\'e}rald E. Pi{\'e}rard},
  pages={227 - 228}
Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib. To the best of our knowledge, the present case of etoricoxib-induced erythema-multiforme-like eruption is the first reported in the literature. 
Etoricoxib-induced pretibial erythema and edema
A case of extoricoxib-induced pretibial erythema and edema and a review of the literature on cox-2 inhibitor side effects is reported. Expand
Fixed drug eruption caused by etoricoxib – 2 cases confirmed by patch testing
This work presents two cases of FDE caused by etoricoxib, a recently developed but widely used selective cyclo-oxygenase (COX) isoenzyme 2 inhibitor, which has rarely been described as a cause ofFDE. Expand
Rare Case of Etoricoxib-Induced Oral Ulceration
Etoricoxib is a highly selective cyclooxygenase 2 (COX-2) inhibitor used to treat chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain in some jurisdictions. The adverse effects ofExpand
Bullous Reactions Associated With COX-2 Inhibitors.
CASE REPORTA 52-year-old man presented with a rash, which had been present for 2 days before his clinic visit. The rash developed 8 days after inception of oral treatment with etoricoxib, 60 mg o.d.Expand
A case report on toxic epidermal necrolysis with etoricoxib
A patient who developed TEN after treatment with etoricoxib for osteoarthritis that later resolved in 15 days after withdrawal and symptomatic treatment is summarized. Expand
Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.
Etoricoxib is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase 2 (cox-2); it was introduced recently onto the market and is used widely. It has been implicated in severalExpand
Etoricoxib-induced fixed drug eruption with positive lesional patch tests
The patch test was reliable for the diagnosis of FDE, avoiding the need for subsequent oral provocation testing and therefore preventing the possible adverse effects of etoricoxib, despite being regarded as a safe drug. Expand
Mucosal exfoliation as a selective reaction to etoricoxib
Etoricoxib is a non‐steroidal anti‐inflammatory drug (NSAID) that inhibits the inducible cyclooxygenase (COX‐2) with a good safety profile.
Oral adverse reactions associated with etoricoxib, a common pain medication.
The dental and medical community should be aware of the oral adverse effects of etoricoxib, recognize them in time, recommend drug-use cessation, and warn patients against repeated use. Expand
Etoricoxib‐induced toxic epidermal necrolysis: Successful treatment with infliximab
Reports are reported on the successful treatment with infliximab of a case of TEN following treatment with etoricoxib, and the evident and rapid efficacy of TNF-a blockade are pointed out. Expand


Fatal allergic vasculitis associated with celecoxib
A previously healthy adult suffered fatal acute multiple organ failure presumably after diffuse allergic vasculitis with diffuse necrotic purpura after treatment with celecoxib, a cyclooxygenase-2 (COX-2) selective, non-steroidal, anti-inflammatory drug. Expand
Acute Generalized Exanthematic Pustulosis: A Case and an Overview of Side Effects Affecting the Skin Caused by Celecoxib and Other COX-2 Inhibitors Reported So Far
A 55-year-old woman who was treated for periarthritis humeroscapularis with celecoxib (Celebrex) developed a generalized pustular exanthema on the head and upper trunk, accompanied by fever, leukocytosis and increased erythrocyte sedimentation rate, and the pustules disappeared without any treatment. Expand
Serious Skin Reactions and Selective COX-2 Inhibitors
A retrospective review of information from reports of serious skin reactions reported during prescription-event monitoring (PEM) studies of rofecoxib, celecoxib, etoricoxib and valdecoxib conducted in England since 1999 provides useful and complementary information to other published studies about serious skin reaction reported during treatment with COX-2 selective inhibitors. Expand
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
These results confirm that most NSAID-sensitive individuals with cutaneous reactions to classic NSAIDs will tolerate specific COX-2 inhibitors, supporting the use of thesedrugs after careful oral provocation in such patients. Expand
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.
Some COX-2 inhibitors, such as rofecoxib, are relatively safe in NSAID-sensitive patients with urticaria or angioedema, however, the tolerance profile varies with the drug, which might be related to a differential selectivity of the drug forCOX-1 and COx-2. Expand
Anti-inflammatory and antirheumatic drugs.
Excerpt Meclofenamate sodium (Meclomen), a nonsteroidal anti-inflammatory agent of the fenamate group, has recently been approved by the U.S. Food and Drug A... Expand
COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
COX-2 inhibitors can also result into increase blood pressure, macular eruptions, urticaria, pseudoporphyria, erythema multiforme, oedema, worsening of heart failure, fatal allergic vasculitis and aggravation of doxorubicin-mediated cardiac injury. Expand
Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
  • J. Quiralte, J. Delgado, +5 authors J. Conde
  • Medicine
  • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2004
The SBPCOCs with highly selective COX-2 inhibitors were safe in patients with single-reactive, NSAID-induced anaphylactoid reactions, even in cases that involved pyrazole derivatives. Expand
Etoricoxib: A Highly Selective COX-2 Inhibitor
Efficacy for acute pain has been evaluated in acute gout, primary dysmenorrhea, and dental surgery and for chronic pain in rheumatoid arthritis, osteoarthritis, and chronic lower back pain and the cardiovascular adverse effects of selective COX-2 inhibition are not well defined. Expand
Le médicament du mois : Etoricoxib (Arcoxia®)
L'efficacite de l'etoricoxib a ete evaluee dans de nombreuses etudes controlees randomisees, montrant une efficacite identique aux autres AINS non selectifs avec moins d'effets secondaires au niveau gastro-intestinal. Expand